Octapharma Octagam Efficacy Claims Are Unsubstantiated, FDA Warning Letter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Promotional materials disseminated by Octapharma at an American Academy of Allergy, Asthma & Immunology meeting also failed to reveal risks associated with use of the intravenous immune globulin.